Human MRP4 Vesicle Kit (HEK293 derived) | ABCC4 | Renal & Hepatic Efflux | 100 Reactions

Is MRP4 relevant for specific drug classes in DDI submissions?

Yes — MRP4 (ABCC4) is most important for three drug classes: (1) nucleotide analogue antivirals (tenofovir, adefovir, cidofovir), where renal MRP4 mediates tubular secretion and inhibition can cause nephrotoxic accumulation; (2) antifolates and cytotoxics (methotrexate, leucovorin), where MRP4 inhibition reduces renal clearance and increases systemic exposure; and (3) NSAIDs and COX inhibitors, which can inhibit MRP4-mediated prostaglandin efflux and alter renal and platelet physiology. MRP4 is not currently a primary Tier 1 DDI transporter under FDA (2020) or EMA (2022) guidance, but it is routinely included in extended renal transporter panels alongside OAT1, OAT3, and OCT2 for the drug classes above.

What probe substrates and inhibitors are used in MRP4 vesicular transport assays?

The most commonly used radiolabelled probe substrates for MRP4 (ABCC4) vesicular transport assays are [³H]-PMEA (adefovir dipivoxil precursor) and [³H]-methotrexate; unlabelled cAMP and estradiol-17β-D-glucuronide (E217βG) are also used with LC-MS/MS detection. For inhibition studies, reference inhibitors include MK571 (pan-MRP inhibitor), probenecid, dipyridamole, and the selective MRP4 inhibitor ceefourin-1. The Cell4Pharma kit protocol provides lot-specific recommendations for probe substrate concentration and incubation conditions to achieve the guaranteed ATP/AMP ratio of >5.

How does MRP4 contribute to antiviral nephrotoxicity, and how does the vesicle assay help?

Nucleotide analogue antivirals such as tenofovir and adefovir are renally excreted primarily via active tubular secretion, which requires uptake from blood into the tubular cell (mediated by OAT1/OAT3 at the basolateral membrane) followed by efflux into urine (mediated by MRP4 at the apical membrane). When MRP4 is inhibited — by a co-administered drug or by the antiviral itself at high doses — the drug accumulates intracellularly in proximal tubule cells, causing mitochondrial toxicity and nephrotoxicity. The MRP4 vesicle assay quantifies the IC₅₀ of a test compound for MRP4-mediated efflux of probe substrate (e.g. PMEA), enabling DDI risk assessment and informing whether dose adjustment or renal monitoring is warranted in combination regimens.

Why is MRP4 relevant in platelet biology and cardiovascular DDI studies?

MRP4 (ABCC4) is expressed at high levels in platelets, where it mediates efflux of cAMP and thromboxane B₂. Intracellular cAMP in platelets acts as an inhibitory second messenger, suppressing platelet activation and aggregation — MRP4 efflux reduces intracellular cAMP, thereby supporting the platelet activation threshold. Inhibition of platelet MRP4 by drugs such as dipyridamole raises intracellular cAMP and inhibits platelet aggregation, contributing to the antiplatelet mechanism of this compound class. For investigational drugs where platelet effects or cardiovascular DDI are a concern, including MRP4 in the transporter profiling panel helps characterise this mechanism.

What documentation is supplied with the Human MRP4 Vesicle Kit?

Every kit shipment includes a lot-specific QC report confirming the ATP/AMP transport ratio (>5) and vesicle preparation parameters, and a data sheet with recommended assay conditions, probe substrates, and reference inhibitor concentrations. All Cell4Pharma kits are manufactured under ISO 9001 and ISO 13485 certified quality systems. Batch reservation for up to 36 months is available on request — particularly important for multi-transporter renal DDI panels where lot-to-lot consistency between the MRP4 kit and matched Control Vesicle Kit must be maintained across the full study duration.